Acadia Pharmaceuticals
ACAD · Pharmaceuticals
$19.73
2.9%Alkermes
ALKS · Pharmaceuticals
$43.63
1.2%The short version
- Alkermes is the larger business, with $1.5B of revenue in fiscal 2025 against $1.1B for Acadia Pharmaceuticals.
- Acadia Pharmaceuticals grew revenue faster (11.9%, against −5.3%).
- Alkermes kept more of each dollar of sales as operating profit (17.2% operating margin, against 9.8% operating margin).
- Alkermes turned more of its sales into free cash flow (32.6% FCF margin, against 9.8% FCF margin).
- Investors pay more for each dollar of Alkermes’s earnings: a P/E of 114.8x against 8.9x for Acadia Pharmaceuticals.
| Latest fiscal year | ACAD · FY25 | ALKS · FY25 |
|---|---|---|
| Size | ||
| Market cap | $3.4B | $7.6B |
| Revenue | $1.1B | $1.5B |
| Free cash flow | $105M | $480M |
| Net income | $391M | $242M |
| Growth | ||
| Revenue growth | 11.9% | −5.3% |
| 5-year growth | 19.4% | 7.3% |
| Share count change | 2.1% | −0.3% |
| Profitability | ||
| Gross margin | 91.7% | 86.7% |
| Operating margin | 9.8% | 17.2% |
| Net margin | 36.5% | 16.4% |
| FCF margin | 9.8% | 32.6% |
| Return on capital | — | — |
| Return on equity | 39.9% | 14.7% |
| Balance sheet | ||
| Net debt | — | — |
| Net debt / EBITDA | — | — |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | 8.9x | 114.8x |
| Piotroski F-score | — | — |
FY16
ACAD $17.3M
ALKS $746M
FY17
ACAD $125M
ALKS $903M
FY18
ACAD $224M
ALKS $1.1B
FY19
ACAD $339M
ALKS $1.2B
FY20
ACAD $442M
ALKS $1.0B
FY21
ACAD $484M
ALKS $1.2B
FY22
ACAD $517M
ALKS $1.1B
FY23
ACAD $726M
ALKS $1.7B
FY24
ACAD $958M
ALKS $1.6B
FY25
ACAD $1.1B
ALKS $1.5B
ACAD
ALKS
FY16
ACAD −1,574.1%
ALKS −28.0%
FY17
ACAD −234.1%
ALKS −16.4%
FY18
ACAD −110.6%
ALKS −9.1%
FY19
ACAD −72.7%
ALKS −15.0%
FY20
ACAD −64.9%
ALKS −10.8%
FY21
ACAD −35.2%
ALKS 8.3%
FY22
ACAD −43.2%
ALKS −0.6%
FY23
ACAD −10.1%
ALKS 24.9%
FY24
ACAD 24.1%
ALKS 27.0%
FY25
ACAD 9.8%
ALKS 17.2%
ACAD
ALKS
FY16
ACAD −$210M
ALKS −$107M
FY17
ACAD −$219M
ALKS −$32.1M
FY18
ACAD −$170M
ALKS $29.9M
FY19
ACAD −$152M
ALKS −$18.9M
FY20
ACAD −$144M
ALKS $40.6M
FY21
ACAD −$127M
ALKS $73.7M
FY22
ACAD −$114M
ALKS −$17.2M
FY23
ACAD $16.7M
ALKS $353M
FY24
ACAD $157M
ALKS $406M
FY25
ACAD $105M
ALKS $480M
ACAD
ALKS
FY16
ACAD —
ALKS −15.5%
FY17
ACAD —
ALKS −11.4%
FY18
ACAD —
ALKS −8.0%
FY19
ACAD —
ALKS −15.9%
FY20
ACAD —
ALKS −11.6%
FY21
ACAD —
ALKS 10.8%
FY22
ACAD —
ALKS −0.6%
FY23
ACAD —
ALKS 57.2%
FY24
ACAD —
ALKS —
FY25
ACAD —
ALKS —
ACAD
ALKS
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.